Evidence map›Paper›PMID 41134086›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

In Situ Assembly of Transformable Monopeptide on Activated Neutrophils Attenuates NETs-Induced Hepatocellular Carcinoma Metastasis by Disrupting NE Nuclear Translocation.

Yichi Chen, Yijun Wang, Haitao Shang, Jiayue Qiu, Ruotian Zhang, Yuxiang Xiong, Tong Wang, Fengyi Wang, Anbang Wu, Xin Lin and 4 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yichi ChenGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Yijun WangGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Haitao ShangDepartment of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Jiayue QiuFaculty of Chinese Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Ruotian ZhangGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Yuxiang XiongGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Tong WangGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Fengyi WangGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Anbang WuGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Xin LinDepartment of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Bolin WuDepartment of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Chen HuangFaculty of Chinese Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Wen ChengDepartment of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Lu ZhangGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.ORCID https://orcid.org/0000-0002-7492-6047

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2024A1515011021First Affiliated Hospital of Harbin Medical University Fund for Excellent Young Scholars 2024YQ06Fundamental Research Funds for the Provincial Universities 2023-KYYWF-0150Guangdong Provincial Key Laboratory of Advanced Biomaterials 2022B1212010003Heilongjiang Postdoctoral Fund LBH-Z23224National Key Research and Development Program of China 2023YFA0915700National Natural Science Foundation of China 52273129National Natural Science Foundation of China 82171947National Natural Science Foundation of China 82403810Shenzhen Science and Technology Innovation Committee 20210324105012034Shenzhen Science and Technology Innovation Committee 20220530114405013
6 · The paper itself

Abstract

Neutrophil extracellular traps (NETs) released by activated neutrophils in the tumor microenvironment has emerged as a pivotal mediator in promoting tumor metastasis. The alteration of the subcellular localization of neutrophil elastase (NE) is crucial for NETs formation. The majority of NE (≈80%) translocate from azurophilic granules to the nucleus, facilitating histone degradation and chromatin decondensation. A few NE are transported to the cell membrane, a unique feature of activated neutrophils that distinguishes them from other leukocyte subpopulations. To address NETs-mediated HCC metastasis, a peptidic nanomaterial (FTP-NPs) is developed that specifically binds NE on activated neutrophil membranes and undergoes in situ fibrillar transformation, forming NE-fibril clusters. These NE-fibril clusters deactivate NE by altering their conformation or binding mode. Subsequently, a series of feedback mechanisms is triggered, which regulates NE membrane concentration by promoting its transport to the membrane rather than the nucleus. The NE-fibril clusters can remain on the activated neutrophil membrane for an extended period, enabling continuous binding and deactivation of newly transported NE, thereby reversing the formation of NETs. Besides, the extracellular NE-fibril clusters also act as a physical barrier to prevent NETs from adhering to tumor cells, further disrupting the metastatic cascade. In vitro, in vivo, and single-cell RNA sequencing (scRNA-seq) data confirm that FTP-NPs significantly reduce NETs formation, reduce metastatic burden, and enhance antitumor immune response. Compared with commercial NE inhibitors, this strategy precisely and locally regulates NE subcellular distribution within neutrophils in tumor tissue, minimizing off-target effects and systemic toxicity. The NE-fibril clusters may establish an innovative therapeutic approach for NETs-mediated tumor metastasis.

Indexed as

Carcinoma, HepatocellularExtracellular TrapsLeukocyte ElastaseLiver NeoplasmsNeutrophilsAnimalsCell Line, TumorCell NucleusHumansMiceNeoplasm MetastasisNeutrophil ActivationTumor MicroenvironmentLeukocyte Elastasehepatocellular carcinoma metastasisin vivo assemblyneutrophil elastaseneutrophil extracellular trapstransformable peptide

Identifiers

PMID41134086
PMCPMC12767106

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.